Idéal Investisseur
Français English
CAC 40 : Market closed
8 203,43 pts
+0.05%


Last updated : 09/06/2026 - 17h29 (last close)
Last close data

OSE IMMUNO news: financial news, earnings, stock moves and analysts

Live news related to OSE IMMUNO stock (FR0012127173): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.

The latest financial news on OSE IMMUNO mainly cover M&A activity et earnings publications. The stock trades at €3,48 on Euronext Paris, down 2,08% at the last update. This page lists the articles published on OSE IMMUNO stock to track the share price, company announcements and any item likely to influence market perception.

Assurance vie
OSE IMMUNO
FR0012127173
Pharmaceuticals & Biotechnology / Biotechnology
3,48 € -2,08 %
High3,63 €
Low3,48 €
Last update : 09/06/2026 - 17:35:21 – Euronext Paris – 15 min delay.
Market closed

Latest OSE IMMUNO stock news

OSE Immunotherapeutics recorded a net loss of €37.7M in 2025, compared to a profit of €37.4M the previous year, while its revenue plummeted by 96% to …

OSE Immunotherapeutics announced on Thursday the signing of a flexible financing agreement structured in the form of warrants with Iris Capital Invest…

OSE Immunotherapeutics announced on Friday the positive results of its Phase 2 TEDOVA study evaluating Tedopi in relapsed ovarian cancer. The combinat…

Nantes-based biotech company OSE Immunotherapeutics sees a 13.39% increase to €4.91 in early afternoon trading on Wednesday. The stock is the second h…

OSE Immunotherapeutics reported its 2025 results on Thursday, marked by a decline in operational revenue from €83.4 million in 2024 to €2.7 million in…

OSE Immunotherapeutics soared on Tuesday, April 28, 2026, marking a 19.74% increase to €4.38 mid-session. The Nantes-based biotech benefited from a re…

OSE Immunotherapeutics surged this Monday, April 27, 2026, at midday, driven by the announcement of an orphan drug designation granted by the FDA to i…

OSE Immunotherapeutics announces that its partner Veloxis Pharmaceuticals has received orphan drug designation from the FDA for pegrizeprument (VEL-10…

OSE Immunotherapeutics announces the selection of its Phase 2 TEDOVA clinical trial results for an oral presentation at the 2026 American Society of C…

OSE Immunotherapeutics announces the presentation of a new FPR2 agonist monoclonal antibody, described as first-in-class, at the 2026 American Associa…

Ad
Chaque matin
Les signaux techniques du marché,
avant l'ouverture.
CAC 40 · SBF 120 · Signaux · Analystes
🤖
Édition du jour — avant bourse
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Signaux haussiers
+5,2%
+1,8%
+0,9%
📉 Signaux baissiers
-14%
-5,7%
🔄 Avis analystes
▲ 35 €
▼ 80 €
Inscrivez-vous pour tout voir →
Avant 9h chaque matin
Données Euronext
Analyse automatique IA